MAPT and Alzheimer disease: As shown in Fig. 4A, Dek silencing led to increased tau levels 4 days after transduction, accompanied by its redistribution to the somatodendritic compartment (Fig. 4C), an early event on AD progression.47,48 These alterations were not accompanied by increased tau phosphorylation at Thr231, generally associated with early AD pathology, or at Ser202/Thr205, associated with later stages of AD pathology49,50 (Supplementary Fig. 4C ad D).